Advertisement

Medical Oncology

, 35:62 | Cite as

De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients

  • Pierfrancesco Franco
  • Giuseppe Carlo Iorio
  • Sara Bartoncini
  • Mario Airoldi
  • Corrado De Sanctis
  • Isabella Castellano
  • Umberto Ricardi
Review Article

Abstract

The reduction in the burden related to treatment is becoming more and more important in modern oncology. Radiation therapy is a mainstay option in the postoperative setting for early breast cancer patients after breast-conserving surgery. Nowadays, different options are available to de-escalate radiotherapy in this scenario such as the use of hypofractionated whole-breast radiation, the selective delivery of the boost dose to the lumpectomy cavity, the introduction of accelerated partial breast irradiation and the omission of treatment in appropriately selected patients with low-risk features. We herein provide a review article on this topic.

Keywords

De-escalation Whole-breast radiation Hypofractionation Accelerated partial breast irradiation Boost Radiotherapy omission Breast cancer 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Poortmans P. Evidence based radiation oncology: breast cancer. Radiother Oncol. 2007;84:84–101.CrossRefPubMedGoogle Scholar
  2. 2.
    Veronesi U, Cascinelli N, Mariani I, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRefPubMedGoogle Scholar
  4. 4.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, et al. Effects of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRefGoogle Scholar
  5. 5.
    Lievens Y. Hypofractionated breast radiotherapy: financial and economic consequences. Breast. 2010;19:192–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Monten C, Lievens Y. Adjuvant breast radiotherapy: how to trade-off cost and effectiveness? Radiother Oncol. 2018;126:132–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Franco P, Zeverino M, Migliaccio F, Sciacero P, Cante D, Casanova Borca V, et al. Intensity-modulated adjuvant whole breast radiation delivered with statics angle tomotherapy (TomoDirect): a prospective case series. J Cancer Res Clin Oncol. 2013;139:1927–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Cante D, Rosa La Porta M, Casanova-Borca V, Sciacero P, Girelli G, Pasquino M, et al. Accelerated hypofractionated adjuvant radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients. Breast J. 2011;17:586–93.CrossRefPubMedGoogle Scholar
  9. 9.
    Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomized trial. Radiother Oncol. 2005;75:9–17.CrossRefPubMedGoogle Scholar
  10. 10.
    The START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet Oncol. 2008;9:331–41.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barret J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomized trials. Lancet Oncol. 2013;14:1086–94.CrossRefPubMedGoogle Scholar
  12. 12.
    Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.CrossRefPubMedGoogle Scholar
  13. 13.
    Owen JR, Ashton A, Bliss JH, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy fraction size on tumor control in patients with early-stage breast cancer after local tumor excision: long-term results of a randomized trial. Lancet Oncol. 2006;7:467–71.CrossRefPubMedGoogle Scholar
  14. 14.
    The START Trialists’ Group. The UK standardization of breast radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–107.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR, START Trial Management Group. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncol. 2010;11:231–40.CrossRefPubMedGoogle Scholar
  16. 16.
    Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Bucholz D, et al. Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol. 2015;1:931–41.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Jagsi R, Griffith KA, Boike TP, Walker E, Nurushev T, Grills IS, et al. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: comparative analysis of physician assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol. 2015;1:918–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Arsenault J, Parpia S, Reiter H, Doherty H, Lukka E, Rakovitch J, et al. Acute toxicity and quality of life of hypofractionated radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2015;93:S59.CrossRefGoogle Scholar
  19. 19.
    Rovea P, Fozza A, Franco P, De Colle C, Cannizzaro A, Di Dio A, et al. Once-weekly hypofractionated whole-breast radiotherapy after breast-conserving surgery in older patients: a potential alternative treatment schedule to daily 3-week hypofractionation. Clin Breast Cancer. 2015;15:270–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol. 2016;120:114–8.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Vicini FA, Baglan KL, Kestin LL, Mitchell C, Chen PY, Frazier RC, et al. Accelerated treatment of breast cancer. J Clin Oncol. 2001;19:1993–2001.CrossRefPubMedGoogle Scholar
  22. 22.
    Klepczyk LC, Keene KS, De Los Santos JF. Accelerated partial breast irradiation for early-stage breast cancer: controversies and current indications for use. Curr Treat Options Oncol. 2013;14:51–65.CrossRefPubMedGoogle Scholar
  23. 23.
    Coles C, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicenter, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390:1048–60.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase-3 randomised controlled trial. Eur J Cancer. 2015;51:451–63.CrossRefPubMedGoogle Scholar
  25. 25.
    Meattini I, Saieva C, Miccinesi G, Desideri I, Francolini G, Scotti V, et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. Eur J Cancer. 2017;51:17–26.CrossRefGoogle Scholar
  26. 26.
    Rodriguez N, Sanz X, Dengra J, Foro P, Membrive I, Reig A, et al. Five-year outcomes, cosmesis and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2013;87:1051–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Meduri B, Baldissera A, Galeandro M, Donini E, Tolento G, Giacobazzi P, et al. Accelerated PBI vs standard radiotherapy (IRMA-trial): interim cosmetic and toxicity results. Radiother Oncol. 2017;123:S303.CrossRefGoogle Scholar
  28. 28.
    NSABP B-39/RTOG 0413. A randomized Phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with Stage 0, I, or II breast cancer. https://www.rtog.org. Accessed 8 Mar 2018.
  29. 29.
    Olivotto I, Whelan T, Parpia S, Kim DH, Berrang T, Truong PT, et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol. 2013;31:4038–45.CrossRefPubMedGoogle Scholar
  30. 30.
    Peterson D, Truong PT, Parpia S, Olivotto IA, Berrang T, Kim DH, et al. Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. Int J Radiat Oncol Biol Phys. 2015;91:968–76.CrossRefPubMedGoogle Scholar
  31. 31.
    Polgar C, Fodor J, Major T, Németh G, Lovey K, Orosz Z, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast caercinoma—5 year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:694–702.CrossRefPubMedGoogle Scholar
  32. 32.
    Polgar C, Fodor J, Major T, Sulyok Z, Kasler M. Breast-conserving therapy with partial or whole breast irradiation: then-year results of the Budapest randomized trial. Radiother Oncol. 2013;108:197–202.CrossRefPubMedGoogle Scholar
  33. 33.
    Lovey K, Fodor J, Major T, Szabo’ E, Orosz Z, Sulyok Z, et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy—4-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:724–31.CrossRefPubMedGoogle Scholar
  34. 34.
    Ott OJ, Strnad V, Hildebrandt Kauer-Dorner D, Knauerhase H, Major T, et al. GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external bream whole breast irradiation: early toxicity and patient compliance. Radiother Oncol. 2016;120:119–23.CrossRefPubMedGoogle Scholar
  35. 35.
    Strnad V, Ott OJ, Hildebrandt GH, Kauer-Dorner D, Knauerhase H, Major T, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: a randomised phase 3, non-inferiority trial. Lancet. 2016;387:229–38.CrossRefPubMedGoogle Scholar
  36. 36.
    Polgar C, Ott OJ, Hildebrandt GH, Kauer-Dorner D, Knauerhase H, Major T, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:259–68.CrossRefPubMedGoogle Scholar
  37. 37.
    Veronesi U, Orecchia R, Maissoneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14:1269–77.CrossRefPubMedGoogle Scholar
  38. 38.
    Leonardi MC, Ivaldi GB, Santoro L, Lazzari R, Ferrari A, Morra A, et al. Long-term side effects and cosmetic outcome in a pool of breast cancer patients treated with intraoperative radiotherapy with electron as sole treatment. Tumori. 2012;98:324–30.CrossRefPubMedGoogle Scholar
  39. 39.
    Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376:91–102.CrossRefPubMedGoogle Scholar
  40. 40.
    Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383:603–13.CrossRefPubMedGoogle Scholar
  41. 41.
    Corica T, Nowak AK, Saunders CM, Bulsara M, Taylor M, Vaidya JS, et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. Int J Radiat Oncol Biol Phys. 2016;96:55–64.CrossRefPubMedGoogle Scholar
  42. 42.
    Bartelink H, Horiot J-C, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001;345:1378–87.CrossRefPubMedGoogle Scholar
  43. 43.
    Bartelink H, Horiot J-C, Poortmans P, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of higher radiation dose on local control, survival in breast-conserving therapy of early breast cancer: 10 years results of the randomized boost versus no boost EORTC trial 22881-10882. J Clin Oncol. 2007;25:3259–65.CrossRefPubMedGoogle Scholar
  44. 44.
    Bartelink H, Maingon P, Poortmans P, Weltesn C, Fourquet A, Jager J, et al. Whole breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow up of a randomised phase 3 trial. Lancet Oncol. 2015;16:47–56.CrossRefPubMedGoogle Scholar
  45. 45.
    Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet JM, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 1997;15:963–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, et al. Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC boost vs no boost trial: a randomized clinical trial. JAMA Oncol. 2017;3:42–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Arcadipane F, Franco P, De Colle C, Rondi N, Di Muzio J, Pelle E, et al. Hypofractionation with no boost after breast conservation in early-stage breast cancer patients. Med Oncol. 2016;33:108.CrossRefPubMedGoogle Scholar
  48. 48.
    Cante D, Franco P, Sciacero P, Girelli G, Marra AM, Pasquino M, et al. Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer. Med Oncol. 2013;30:518.CrossRefPubMedGoogle Scholar
  49. 49.
    Cante D, Franco P, Sciacero P, Girelli G, Marra AM, Pasquino M, et al. Hypofractionation and concomitant boost to deliver adjuvant whole-breast radiation in ductal carcinoma in situ (DCIS): a subgroup analysis of a prosepctive cohort. Med Oncol. 2014;31:838.CrossRefPubMedGoogle Scholar
  50. 50.
    Cante D, Petrucci E, Sciacero P, Piva C, Ferrario S, Bagnera S, et al. Ten-year results of accelerated hypofractionated adjuvant whole-breast radiation with concomitant boost to the lumpectomy cavity after conserving surgery for early breast cancer. Med Oncol. 2017;34:152.CrossRefPubMedGoogle Scholar
  51. 51.
    Franco P, Zeverino M, Migliaccio F, Cante D, Sciecero P, Casanova Borca V, et al. Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing static port of tomotherapy (TomoDirect): a prospective phase II trial. J Cancer Res Clin Oncol. 2014;140:167–77.CrossRefPubMedGoogle Scholar
  52. 52.
    Franco P, Cante D, Sciacero P, Girelli G, La Porta MR, Ricardi U. Tumor bed boost integration during whole breast radiotherapy: a review of the current evidence. Breast Care. 2015;10:44–9.CrossRefPubMedGoogle Scholar
  53. 53.
    RTOG 1005. A Phase III trial of accelerated whole breast irradiation with hypofractionation plus concurrent boost versus standard whole breast irradiation plus sequential boost for early-stage breast cancer. www.rtog.org. Accessed 3 Mar 2018.
  54. 54.
    Coles C, Yarnold J, IMPORT Trials Management Group. The IMPORT trials are launched (September 2006). Clin Oncol. 2006;18:587–90.CrossRefGoogle Scholar
  55. 55.
    Askoxylakis V, Jensen AD, Hafner MF, Fetzner L, Sterzing F, Heil J, et al. Simultaneous integrated boost for adjuvant treatment of breast cancer—intensity modulated vs conventional radiotherapy: the IMRT-MC2 trial. BMC Cancer. 2011;11:249.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Van Parijs H, Miedema G, Vinh-Hung V, Verbanck S, Adriaenssens N, Kerkhove D, et al. Shourt course radiotherapy with simultaneous integrated boost for stage I–II breast cancer, early toxicities of a randomized trial. Radiat Oncol. 2012;7:80.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20:4141–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Winzer KJ, Sauer R, Sauerbrei W, Schneller E, Jaeger W, Braun M, et al. Radiation therapy after breast-conserving surgery: first results of a randomised clinical trial in patients with low risk of recurrence. Eur J Cancer. 2004;40:998–1005.CrossRefPubMedGoogle Scholar
  59. 59.
    Blamey RW, Bates T, Chetty U, Duffy SW, Ellis IO, George D, et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer. 2013;49:2294–302.CrossRefPubMedGoogle Scholar
  60. 60.
    Fyles AW, McCready D, Manchul LA, Trudeau ME, Merante P, Pintillie M, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):963–70.CrossRefPubMedGoogle Scholar
  61. 61.
    Tinterri C, Gatzemeier W, Costa A, Gentilini MA, Zanini V, Regolo L, et al. Breast-conservative surgery with and without radiotherapy in patients aged 55–75 years with early-stage breast cancer: a prospective, randomized, multicenter trial analysis after 108 months of median follow-up. Ann Surg Oncol. 2014;21:408–15.CrossRefPubMedGoogle Scholar
  62. 62.
    Potter R, Gnant M, Kwasny W, Tausch C, Handl-Zeller L, Pakisch B, et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys. 2007;68:334–40.CrossRefPubMedGoogle Scholar
  63. 63.
    Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: log-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382–7.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM. PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16:266–73.CrossRefPubMedGoogle Scholar
  65. 65.
    Liu FF, Shi W, Done SJ, Miller N, Pintillie M, Voduc D, et al. Identification of a low-risk luminal A breast cancer cohort that may not benefit from breast radiotherapy. J Clin Oncol. 2015;33:1–6.Google Scholar
  66. 66.
    Bhattacharya IS, Kirby A, Bliss JM, Coles CE. Can interrogation of tumor characteristics lead us to safely omit adjuvant radiotherapy in patients with early breast cancer? Clin Oncol. 2018;30:158–65.CrossRefGoogle Scholar
  67. 67.
    The IDEA (Individualized Decisions for Endocrine therApy) study at ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02400190. Accessed 10 Mar 2018.
  68. 68.
    Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28:1677–83.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    The PRECISION (Profiling Early Breast Cancer for Radiotherapy Omission) trial at ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02653755. Accessed 10 Mar 2018.
  70. 70.
    Dowsett M, Sestak I, Lopez-Knowles E, Sidhy K, Dunbier AK, Cowens JW, et al. Comparison of PAM50 risk of recurrence score with Oncotype Dx and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31:2783–90.CrossRefPubMedGoogle Scholar
  71. 71.
    Cuzik J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273–8.CrossRefGoogle Scholar
  72. 72.
    A prospective cohort study evaluating risk of local recurrence following breast conserving surgery and endocrine therapy in low risk LUMINAL A Breast cancer (LUMINA) at ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01791829. Accessed 10 Mar 2018.
  73. 73.
    Kirwan CC, Coles CE, Bliss J. It’s PRIMETIME. Postoperative avoidance of radiotherapy: biomarker selection of women at very low risk of local recurrence. Clin Oncol. 2016;28:594–6.CrossRefGoogle Scholar
  74. 74.
    Poortmans PMP, Arenas M, Livi L. Over-irradiation. Breast. 2017;31:295–302.CrossRefPubMedGoogle Scholar
  75. 75.
    Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28:1700–12.CrossRefPubMedGoogle Scholar
  76. 76.
    Filippi AR, Franco P, Ricardi U. Is clinical radiosensitivity a complex genetically controlled event? Tumori. 2006;92:87–91.PubMedGoogle Scholar
  77. 77.
    Cante D, Franco P, Sciacero P, Girelli G, Pasquino M, Borca Casanova, et al. Hypofractionated whole-breast radiotherapy and concomitant boost after breast conservation in elderly patients. Tumori. 2016;102:196–202.CrossRefPubMedGoogle Scholar
  78. 78.
    Franco P, Freedman GM, Ricardi U, Poortmans P. ‘Simplicity is complexity resolved’: the case of postoperative radiation therapy after breast conservation. Transl Cancer Res. 2016;5:S1336–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Oncology, Radiation OncologyUniversity of TurinTurinItaly
  2. 2.Department of Oncology, Radiation OncologyAOU Citta’ della Salute e della ScienzaTurinItaly
  3. 3.Department of Medical Sciences, Pathology UnitUniversity of TurinTurinItaly
  4. 4.Department of Gynecology and Obstetrics, Breast UnitAOU Città della Salute e della ScienzaTurinItaly
  5. 5.Department of Oncology, Medical Oncology 2AOU Città della Salute e della ScienzaTurinItaly

Personalised recommendations